Clinical trials: Psoriasis; Plaque
Moderate to Severe Chronic Plaque Psoriasis
A Study of Multiple Doses of AbGn-168H by Intravenous Infusion in Patients With Moderate to Severe Chronic Plaque Psoriasis
This is a phase II, randomised, double-blind, placebo-controlled, multiple-dose, multi-center study of AbGn-168H in subjects with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT02223039
- Testing
- AbGn-168H
- Where
- 15 sites in United States
- Volunteers
- 50 people
- Sponsor
- AbGenomics B.V Taiwan Branch
Plaque Psoriasis
A Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-1139 Injection in Patients With Plaque Psoriasis
This study is a randomized, double-blind, multicenter, dose-parallel-controlled phase II clinical trial. The study consists of three stages: a 4-week screening period, a 52-week treatment period, and a 12-week follow-up period.
- Trial name
- NCT07758075
- Testing
- SHR-1139, SHR-1139 and SHR-1139 pleacebo
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Psoriasis
A Study of the Safety and Effectiveness of Ustekinumab (Stelara) in Chinese Patients With Psoriasis
The purpose of this study is to evaluate the efficacy (good or bad effects) and safety of ustekinumab in the treatment of patients with moderate to severe psoriasis in China.
- Trial name
- NCT01008995
- Testing
- ustekinumab
- Where
- 9 sites in China
- Volunteers
- 322 people
- Sponsor
- Centocor, Inc.
Plaque Psoriasis
A Study to Assess the Safety and Effectiveness of COL-5671-PRO Capsules in Adults With Moderate-to-Severe Plaque Psoriasis
The main purpose of this study is to assess how-well COL-5671-PRO works (clinical efficacy), how safe it is (safety), and how well it is tolerated (tolerability) when compared to placebo (a look-alike substance that contains no…
- Trial name
- NCT07914231
- Testing
- COL-5671-PRO
- Where
- 6 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Coultreon Biopharma
Moderate Plaque Psoriasis
A Study of Treatment With APRemilast in Moderate psoriAsIS in Real Life clinicAL Practice (The 'APRAISAL' Study)
For patients with moderate plaque psoriasis who are intolerable to, have a contraindication to or have failed classical systemic treatments, the current commonly employed management strategy encompasses treatment with biologic…
- Trial name
- APRAISAL (NCT03059953)
- Where
- Greece
- Volunteers
- 302 people
- Sponsor
- Genesis Pharma S.A.
Plaque-type Psoriasis
AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis
The purpose of this study was to provide long term clinical data for the compound for the treatment of the indication of moderate to severe chronic plaque-type psoriasis.
- Trial name
- NCT01132612
- Testing
- AIN457
- Where
- 57 sites in United States, France and 5 more
- Volunteers
- 275 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Evaluation of the Efficacy and Tolerability of Clobetasol Propionate Foam Compared to Vehicle Foam
The purpose of the study is to compare the efficacy and safety of Clobetasol propionate to that of its Vehicle in the treatment of mild to moderate plaque-type psoriasis.
- Trial name
- NCT00842153
- Testing
- Clobetasol propionate foam, Vehicle foam
- Where
- 2 sites in United States
- Volunteers
- 58 people
- Sponsor
- Stiefel, a GSK Company
Psoriasis, Psoriasis; Plaque
Ceramol PSOR Cream as an Adjuvant Treatment in Patients With Mild-to-Moderate Psoriasis Treated With Narrowband UVB Phototherapy (CERAMOL PSOR CREMA)
This is a multicenter, prospective, randomized, open-label, controlled clinical investigation to evaluate whether Ceramol PSOR cream, used as an adjuvant treatment, is superior to a comparator emollient cream in patients with…
- Conditions
- Psoriasis, Psoriasis; Plaque, Psoriasis Vulgaris
- Trial name
- CERAMOL PSOR C (NCT07849101)
- Testing
- Narrowband UVB Phototherapy, Ceramol PSOR Cream, Comparator Emollient Cream
- Where
- 3 sites in Spain
- Volunteers
- 128 people
- Sponsor
- Unifarco SpA
Psoriasis
Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis
The purpose of the study is to evaluate the efficacy, safety, pharmacokinetics, immunogenicity, usability, and acceptability of guselkumab delivered using SelfDose device in participants with moderate to severe plaque-type…
- Trial name
- NCT02905331
- Testing
- Guselkumab
- Where
- 14 sites in United States, Canada and 1 more
- Volunteers
- 78 people
- Sponsor
- Janssen Research & Development, LLC
Plaque Psoriasis
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
This is a multicenter, randomized, double-blinded, placebo-controlled, proof-of-concept study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of ORKA-001 in adult participants with moderate-to-severe plaque…
- Trial name
- EVERLAST-A (NCT07090330)
- Testing
- ORKA-001 Induction Dose, ORKA-001 Maintenance Dose
- Where
- 26 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- Oruka Therapeutics, Inc.
Psoriasis
A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis
This was a Phase 2, international, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, 12-week study. It was designed to assess the therapeutic dose, efficacy, and safety of treatment with SAR441566 in male…
- Trial name
- SPECIFI-PSO (NCT06073119)
- Testing
- SAR441566
- Where
- 51 sites in United States, Argentina and 15 more
- Volunteers
- 221 people
- Sponsor
- Sanofi
Plaque Psoriasis
A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy
This multicenter, randomized, double-blind, active-controlled study aims to evaluate the efficacy and safety of picankibart in Chinese patients with plaque psoriasis who demonstrated inadequate responses to interleukin-17 (IL-17)…
- Trial name
- NCT06945107
- Testing
- Picankibart, Secukinumab, Ixekizumab
- Where
- China
- Volunteers
- 308 people
- Sponsor
- Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Plaque Psoriasis
Efficacy and Safety of Tildrakizumab 100 Milligrams (mg) in Participants With Moderate-Severe Chronic Plaque Psoriasis and Its Impact on Their Quality of Life (TRIBUTE)
The main aim of the study is to evaluate the efficacy, safety and impact on the health-related quality of life (HRQoL) in participants with moderate-to-severe chronic plaque psoriasis who are treated with tildrakizumab 100…
- Trial name
- TRIBUTE (NCT04229836)
- Testing
- Tildrakizumab 100 mg Solution for Injection
- Where
- 39 sites in Italy, Spain
- Volunteers
- 178 people
- Sponsor
- Almirall, S.A.
Psoriasis
A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis
The study was double-blind, randomized, vehicle-controlled study with application of Ruxolitinib phosphate cream or vehicle cream in participants with stable plaque psoriasis applied once daily for 12 weeks without occlusive…
- Trial name
- NCT00778700
- Testing
- Ruxolitinib Phosphate
- Where
- 28 sites in United States
- Volunteers
- 199 people
- Sponsor
- Incyte Corporation
Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasis
The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque Psoriasis
The purpose of this study is to assess efficacy, safety of subcutaneous SHR-1314 in pediatric patients of age 6 to <18 years with moderate-to-Severe plaque psoriasis
- Trial name
- NCT06833307
- Testing
- SHR-1314
- Where
- 2 sites in China
- Volunteers
- 90 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Psoriasis
Efficacy and Safety of Topical ALT-2074 (SYI-2074) for Treatment of Chronic Plaque Psoriasis
The primary objective of this study will be to evaluate the efficacy of topical ALT-2074 applied twice daily for 28 days for treatment of chronic plaque psoriasis in adult subjects.
- Trial name
- NCT00782613
- Testing
- 4,4-dimethyl-benziso-2H-selenazine
- Where
- 3 sites in Israel
- Volunteers
- 30 people
- Sponsor
- Synvista Therapeutics, Inc
Psoriasis Vulgaris
Long Term Safety and Efficacy Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
The objective of this study is to evaluate the safety and efficacy of up to 26 weeks of treatment with calcitriol 3 mcg/g ointment when used twice daily, without occlusion, to treat pediatric subjects (2 to 16 years and 11 months…
- Trial name
- NCT02125279
- Testing
- Calcitriol
- Where
- 16 sites in United States, Belgium and 3 more
- Volunteers
- 54 people
- Sponsor
- Galderma R&D
Plaque Psoriasis
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis
The purpose of this pediatric study is to evaluate the drug levels, efficacy and safety of Deucravacitinib in children and adolescent participants aged 4 to <18 years with moderate to severe plaque psoriasis.
- Trial name
- NCT04772079
- Testing
- Deucravacitinib
- Where
- 65 sites in Argentina, Australia and 11 more
- Volunteers
- 153 people
- Sponsor
- Bristol-Myers Squibb
Plaque Psoriasis
A Study to Evaluate the Effects of Efalizumab on Immune Responses in Subjects With Moderate Plaque Psoriasis
This is a Phase I, randomized, placebo-controlled, single blind, parallel group, single-center study designed to evaluate immune responses during and after administration of 12 weekly SC doses of 1.0 mg/kg efalizumab in subjects…
- Trial name
- NCT00382512
- Testing
- Raptiva (efalizumab)
- Volunteers
- 60 people
- Sponsor
- Genentech, Inc.
Plaque Psoriasis
Exploratory Study to Evaluate the Application of NLAC Cream in Adults With Plaque Psoriasis
Psoriasis is a chronic and immune mediated skin disorder that presents with plaques of thickened, scaly skin. Up to 71% patients suffer from psoriasis, leading to high impact on their daily life.
- Trial name
- NCT05078567
- Testing
- 5% Natural Lactic Acid-enriched Cream
- Volunteers
- 10 people
- Sponsor
- Microbio Co Ltd